Larimar Therapeutics (LRMR) News Today $3.19 -0.08 (-2.45%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$3.20 +0.00 (+0.16%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Larimar Therapeutics (LRMR) Gets a Buy from JMP SecuritiesFebruary 19 at 2:38 PM | markets.businessinsider.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from AnalystsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) has earned a consensus rating of "Buy" from the twelve research firms that are currently covering the stock, MarketBeat reports. Eleven equities research analysts have rated the stock with a buy recommendation and one has given a strong buFebruary 1, 2025 | marketbeat.comLarimar started at buy by Truist on Friedreich's ataxia drugJanuary 30, 2025 | msn.comTruist Securities Initiates Coverage of Larimar Therapeutics (LRMR) with Buy RecommendationJanuary 30, 2025 | msn.comLarimar Therapeutics initiated with a Buy at TruistJanuary 29, 2025 | markets.businessinsider.comTruist sees ‘significant upside’ for Larimar Therapeutics, starts with a BuyJanuary 29, 2025 | markets.businessinsider.comLarimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Truist FinancialTruist Financial initiated coverage on shares of Larimar Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $18.00 price target for the company.January 29, 2025 | marketbeat.comLarimar Therapeutics Aligns Executive Incentives with MilestonesJanuary 27, 2025 | msn.comLarimar Therapeutics awards key executives performance-based stockJanuary 27, 2025 | msn.comOptimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s AtaxiaJanuary 27, 2025 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics: Promising Pediatric Study and Robust Growth ProjectionsJanuary 25, 2025 | markets.businessinsider.comLarimar Therapeutics' SWOT analysis: stock potential hinges on FA treatmentJanuary 24, 2025 | msn.comLarimar Therapeutics’ Promising Developments and Strategic Positioning Signal Buy OpportunityJanuary 24, 2025 | markets.businessinsider.comPromising Developments and Safety Confidence Boost Larimar Therapeutics’ OutlookJanuary 24, 2025 | markets.businessinsider.comJMP Securities maintains $21 target on Larimar Therapeutics stockJanuary 24, 2025 | msn.comLarimar Therapeutics (NASDAQ:LRMR) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Larimar Therapeutics in a research report on Friday.January 24, 2025 | marketbeat.comLarimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's AtaxiaJanuary 23, 2025 | globenewswire.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from AnalystsShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given an average recommendation of "Buy" by the eleven research firms that are covering the stock, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy ratiJanuary 7, 2025 | marketbeat.comBullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of StockJanuary 6, 2025 | finance.yahoo.comGeode Capital Management LLC Decreases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR)Geode Capital Management LLC cut its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 20.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 901,262 shares of the company's stock afteJanuary 5, 2025 | marketbeat.comLarimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get BetterJanuary 3, 2025 | seekingalpha.comHC Wainwright Has Negative Outlook for LRMR FY2025 EarningsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Larimar Therapeutics in a research note issued to investors on Monday, December 16th. HC Wainwright analyst E. White now anticipates that the company will eDecember 19, 2024 | marketbeat.comWilliam Blair Has Pessimistic Outlook of LRMR Q1 EarningsLarimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at William Blair lowered their Q1 2025 earnings estimates for Larimar Therapeutics in a research note issued on Monday, December 16th. William Blair analyst M. Minter now anticipates that the company will post earnings pDecember 19, 2024 | marketbeat.comLarimar Therapeutics Reports Promising Results for Friedreich’s Ataxia TreatmentDecember 19, 2024 | msn.comOppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)December 17, 2024 | markets.businessinsider.comAnalyst Recommends ‘Buy’ on Larimar Therapeutics Despite Market Concerns Over Safety DataDecember 17, 2024 | markets.businessinsider.comLarimar Therapeutics announces initial data from OLE study of nomlabofuspDecember 17, 2024 | finance.yahoo.comHC Wainwright Reaffirms "Buy" Rating for Larimar Therapeutics (NASDAQ:LRMR)HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Larimar Therapeutics in a report on Monday.December 16, 2024 | marketbeat.comLarimar Reports Positive Initial Data From Long-term OLE Study Of Nomlabofusp In Friedreich's AtaxiaDecember 16, 2024 | markets.businessinsider.comLarimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's AtaxiaDecember 16, 2024 | globenewswire.comPoint72 Asset Management L.P. Has $1.36 Million Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)Point72 Asset Management L.P. reduced its holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 65.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,100 shares of the company's stocDecember 11, 2024 | marketbeat.comJanus Henderson Group PLC Purchases 1,189,467 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)Janus Henderson Group PLC increased its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 27.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,566,855 shares of the company's stock after buying anDecember 7, 2024 | marketbeat.comPositive Outlook on Larimar Therapeutics’ Nomlabofusp for Friedreich’s Ataxia: Analyst Recommends Buy RatingDecember 6, 2024 | markets.businessinsider.comVerition Fund Management LLC Decreases Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)Verition Fund Management LLC lowered its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 27.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,161,750 shares ofDecember 2, 2024 | marketbeat.comFred Alger Management LLC Sells 146,906 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)Fred Alger Management LLC reduced its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 15.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 786,588 shares of the company's stock after selling 146,906 shares during tDecember 1, 2024 | marketbeat.comLarimar Therapeutics Gains Buy Rating for Strategic Advances and Promising Data on NomlabofuspNovember 21, 2024 | markets.businessinsider.comLarimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research CongressNovember 21, 2024 | msn.comLarimar Therapeutics (NASDAQ:LRMR) Given "Outperform" Rating at William BlairWilliam Blair reaffirmed an "outperform" rating on shares of Larimar Therapeutics in a research report on Tuesday.November 19, 2024 | marketbeat.comPromising Prospects for Larimar Therapeutics: Analyst Upgrades Stock to Buy Amid Positive Drug Developments and Strong Financial OutlookNovember 19, 2024 | markets.businessinsider.comLarimar Therapeutics presents Phase 1 and 2 dose studies of nomlabofuspNovember 19, 2024 | markets.businessinsider.comLarimar Therapeutics (NASDAQ:LRMR) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Larimar Therapeutics in a report on Monday.November 18, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Rating of "Buy" from AnalystsShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given a consensus rating of "Buy" by the ten analysts that are presently covering the company, MarketBeat.com reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recoNovember 18, 2024 | marketbeat.comIs Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comWhat is HC Wainwright's Forecast for LRMR FY2024 Earnings?Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at HC Wainwright upped their FY2024 earnings estimates for Larimar Therapeutics in a note issued to investors on Wednesday, October 30th. HC Wainwright analyst E. White now forecasts that the company will post earnings ofNovember 4, 2024 | marketbeat.comOppenheimer Keeps Their Buy Rating on Larimar Therapeutics (LRMR)November 2, 2024 | markets.businessinsider.comAssenagon Asset Management S.A. Sells 383,554 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)Assenagon Asset Management S.A. lessened its holdings in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 62.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 226,475 shares of the compaNovember 2, 2024 | marketbeat.comLarimar Therapeutics Reports Third-Quarter 2024 Financial and Operational ProgressOctober 31, 2024 | msn.comCiti opens ‘positive catalyst watch’ on Larimar Therapeutics into dataOctober 31, 2024 | markets.businessinsider.comLarimar Therapeutics Q3 2024 Financial UpdateOctober 31, 2024 | markets.businessinsider.comLarimar Therapeutics (NASDAQ:LRMR) Posts Earnings Results, Beats Estimates By $0.13 EPSLarimar Therapeutics (NASDAQ:LRMR - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.13. During the same quarter last year, the company posted ($0.21) earnings per share.October 31, 2024 | marketbeat.com Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address LRMR Media Mentions By Week LRMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LRMR News Sentiment▼0.000.60▲Average Medical News Sentiment LRMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LRMR Articles This Week▼13▲LRMR Articles Average Week Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ginkgo Bioworks News Immunome News Avadel Pharmaceuticals News CureVac News Avid Bioservices News Nuvation Bio News Prothena News Cronos Group News GH Research News Bicara Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LRMR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
